uniQure N.V. (LON:0EE0)

Market Cap	566.04M
Revenue (ttm)	10.46M
Net Income (ttm)	-145.25M
Shares Out	n/a
EPS (ttm)	-2.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,098
Average Volume	5,165
Open	15.39
Previous Close	14.92
Day's Range	12.35 - 15.39
52-Week Range	4.46 - 19.13
Beta	n/a
RSI	44.84
Earnings Date	Aug 8, 2025

About R1 RCM

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 209
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0EE0

Financial Performance

In 2024, uniQure's revenue was $27.12 million, an increase of 71.17% compared to the previous year's $15.84 million. Losses were -$239.56 million, -22.34% less than in 2023.